Liverpool HIV Interactions

HIV Drug Interactions

Interaction Checker

Apps

Download from the AppStore

Download from Google Play

Interaction Checker

About Us

Mission Statement Meet the Team Steering Committee

Interaction Checkers

Interaction Checker Español Checker Português Checker Interaction Checker Lite View All Checker

Prescribing Resources Videos Site News

Feedback Form Suggest a Drug

Support Us

Cookies help us deliver our services. By using our services, you agree to our use of cookies. Learn more

Potential Interaction

Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir alafenamide (EVG/c/FTC/TAF)

Voriconazole

Quality of Evidence: Very Low

Summary:

Coadministration has not been studied. Voriconazole is a strong inhibitor of CYP3A4 and may increase plasma concentrations of elvitegravir/cobicistat. Concentrations of voriconazole may also increase. When coadministration is required, an assessment of benefit/risk ratio is recommended to justify the use of voriconazole. Emtricitabine and tenofovir alafenamide do not interact with voriconazole metabolic pathway.

Description:

Interaction not studied with any of the components of Genvoya. Concentrations of voriconazole may increase or decrease when co-administered with Genvoya. Clinical monitoring should be made upon co-administration with Genvoya. An assessment of benefit/risk ratio is recommended to justify use of voriconazole with Genvoya.
Genvoya Summary of Product Characteristics, Gilead Sciences International Ltd, November 2021.

Coadministration is expected to increase concentrations of elvitegravir, cobicistat and voriconazole. An assessment of benefit/risk ratio is recommended to justify use of voriconazole with Genvoya.

Genvoya US Prescribing Information, Gilead Sciences Inc, September 2021.

View all available interactions with Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir alafenamide (EVG/c/FTC/TAF) by clicking here.